New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
Baune, Bernhard T. (2008) New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine. Neuropsychiatric Disease and Treatment, 4 (6). pp. 1181-1191.
|PDF (Published Version) - Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://www.ncbi.nlm.nih.gov/pmc/articles...
Quetiapine has demonstrated efficacy in schizophrenia, bipolar disorder and in the treatment of specific symptom clusters such as agitation and sleep problems in mood disorders. In this review, randomized controlled studies demonstrating efficacy, safety and tolerability of quetiapine in major depressive disorder (MDD) and general anxiety disorder (GAD) are evaluated. The results show that quetiapine monotherapy and quetiapine augmentation of antidepressant treatment in MDD and GAD are efficacious for short-term and maintenance treatment at a dose range between 50 and 300 mg/day. Quetiapine appears to have a specific but overall mild side-effect profile, though, some adverse effects such as sedation and somnolence may lead to withdrawal from treatment in some patients. Overall, the available evidence suggests that there is a significant role for quetiapine in the treatment of MDD and GAD.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||quetiapine; major depressive disorders; general anxiety disorder; randomized controlled studies; adverse effects|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1103 Clinical Sciences > 110319 Psychiatry (incl Psychotherapy) @ 100%|
|SEO Codes:||92 HEALTH > 9204 Public Health (excl. Specific Population Health) > 920410 Mental Health @ 100%|
|Deposited On:||31 Mar 2010 09:46|
|Last Modified:||12 Dec 2011 11:40|
Last 12 Months: 0
|Citation Counts with External Providers:|
Repository Staff Only: item control page